Pergolide_Methanesulfonate
Category
Pergolide_Methanesulfonate Brand names, Pergolide_Methanesulfonate Analogs
Pergolide_Methanesulfonate Brand Names Mixture
No information avaliable
Pergolide_Methanesulfonate Chemical_Formula
C19H26N2S
Pergolide_Methanesulfonate RX_link
http://www.rxlist.com/cgi/generic2/pergol.htm
Pergolide_Methanesulfonate fda sheet
Pergolide_Methanesulfonate msds (material safety sheet)
Pergolide_Methanesulfonate Synthesis Reference
No information avaliable
Pergolide_Methanesulfonate Molecular Weight
314.489 g/mol
Pergolide_Methanesulfonate Melting Point
207.5 oC
Pergolide_Methanesulfonate H2O Solubility
No information avaliable
Pergolide_Methanesulfonate State
Solid
Pergolide_Methanesulfonate LogP
4.02
Pergolide_Methanesulfonate Dosage Forms
Tablet
Pergolide_Methanesulfonate Indication
Indicated as adjunctive treatment to levodopa/carbidopa in the management of the signs and symptoms of Parkinson’s disease.
Pergolide_Methanesulfonate Pharmacology
Pergolide is an ergot derivative dopamine receptor agonist at both D1 and D2 receptor sites. Pergolide is 10 to 1,000 times more potent than bromocriptine on a milligram per milligram basis in various in vitro and in vivo test systems. Pergolide mesylate inhibits the secretion of prolactin in humans; it causes a transient rise in serum concentrations of growth hormone and a decrease in serum concentrations of luteinizing hormone. In Parkinson’s disease, pergolide mesylate is believed to exert its therapeutic effect by directly stimulating postsynaptic dopamine receptors in the nigrostriatal system.
Pergolide_Methanesulfonate Absorption
Significant amount may be absorbed (evidence on bioavailability still lacking).
Pergolide_Methanesulfonate Toxicity
Oral, rat LD50: 15 mg/kg. Symptoms of overdose include nausea, vomiting, convulsions, decreased blood pressure, and CNS stimulation.
Pergolide_Methanesulfonate Patient Information
Pergolide_Methanesulfonate Organisms Affected
Humans and other mammals
